Please assess the completion status of the following clinical trial:

Trial Title: Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients meeting all the following criteria will be enrolled in the study:~  1. Aged between 20 and 75 years old.~ 2. Diagnosis of T2DM according to the criteria of the American Diabetes Association (ADA).~ 3. Not having received treatment with oral hypoglycemic agents or insulin within 12 weeks prior to the screening visit;~ 4. Glycated hemoglobin (HbA1c) levels at the screening visit of 7.5% ≤ HbA1c ≤ 10.5%, after appropriate treatment with diet and physical exercise for ≥ 12 weeks;~ 5. Body mass index (BMI) of 20 kg/m2 ≤ BMI ≤ 40 kg/m2 at the screening visit.~ 6. Signing the Informed Consent Form (ICF) before the performance of any study procedure.~Exclusion Criteria:~- Patients meeting at least one of the following criteria will be excluded from the study:~1. Fasting blood glucose values \> 300 mg/dL with severe clinical manifestations present (significant loss weight, severe symptoms and/or ketonuria).~2. Current participation in weight loss programs, with or without anti-obesity drugs use.~3. Presence of heart failure functional class III or IV according to the New York Heart Association (NYHA).~4. Presence of symptomatic liver or gall bladder disease.~5. History of myocardial infarction, transient ischemic attack or coronary angioplasty within 6 months prior to the screening visit.~6. History of gastrointestinal resection.~7. Estimated creatinine clearance (Cockroft and Gault formula) \< 60 mL/min.~8. Serum ALT and/or AST level ≥ 2.5 x upper normal limit.~9. Serum CPK level ≥ 3 x upper normal limit.~10. Fasting triglycerides \> 400 mg/dL.~11. History of major skin allergy.~12. Use of corticosteroids within 3 months prior to the screening visit.~13. Concomitant treatment with warfarin, dicoumarinic agents or digoxin.~14. Concomitant use of drugs or foods that interfere with the CYP3A4 pathway of liver metabolism including, but not limited to:~    * Inhibitors: antibacterial agents (erythromycin), antifungals (itraconazole, ketoconazole), antivirals (ritonavir, saquinavir, amprenavir, indinavir, nelfinavir), H2 receptor antagonists (cimetidine) and grapefruit juice;~   * Inducers: dexamethasone, rifampin and anticonvulsants (phenytoin, phenobarbital, carbamazepine)~15. History of untreated or uncontrolled thyroid disorder.~16. History of drugs of abuse or moderate/heavy alcohol consumption within 2 months prior to screening.~17. Presence of severe or uncontrolled diseases.~18. Presence of pregnancy or breastfeeding.~19. Women of childbearing potential who do not agree to use a proven effective contraceptive method, unless they are surgically sterile or declare being expressly exempt of pregnancy risk for not engaging in sexual practices or for engaging in them in a non-reproductive manner.~20. Participation in a clinical trial protocol within the previous 12 months unless, at the investigator's discretion, his or her participation may imply a direct benefit for the participant.~21. Presence of any condition which, at the investigator's discretion, may render the patient inadequate for study participation.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Evogliptin 2.5mg+Placebo Sitagliptin (Type: EXPERIMENTAL): Evogliptin (EVO) will be administered orally at a daily dose of: 2.5 mg. The participants randomized to this group will receive 1 tablet daily of EVO 2.5 mg + 1 tablet of sitagliptin (SITA) placebo for 12 weeks.
- Evogliptin 5.0mg+Placebo Sitagliptin (Type: EXPERIMENTAL): Evogliptin (EVO) will be administered orally at a daily dose of: 5.0 mg. The participants randomized to this group will receive 1 tablet daily of EVO 5.0 mg + 1 tablet of sitagliptin (SITA) placebo for 12 weeks.
- Evogliptin 10.0mg+Placebo Sitagliptin (Type: EXPERIMENTAL): Evogliptin (EVO) will be administered orally at a daily dose of: 10.0 mg. The participants randomized to this group will receive 1 tablet daily of EVO 10.0 mg + 1 tablet of sitagliptin (SITA) placebo for 12 weeks.
- Sitagliptin 100mg+Placebo Evogliptin (Type: ACTIVE_COMPARATOR): SITA at a daily oral dose of 100 mg. The participants randomized to this group will receive 1 tablet daily of SITA 100 mg + 1 tablet of EVO placebo for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).